Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLD1 | Q13393 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 7/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4173238 | 0.75 | ADRB2 (0.42) | PLD1ALDH1A1 | |
| SCHEMBL17329309 | 0.71 | ALDH1A1 (0.43) | PLD1TRPM8ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL31511748 | 0.71 | PLD1 (0.43) | PLD1ALDH1A1SMN1; SMN2NPSR1HTR7 | |
| SCHEMBL8715074 | 0.71 | PLD1 (0.45) | PLD1ALDH1A1SMN1; SMN2HTR7 | |
| SCHEMBL1306110 | 0.68 | JAK3 (0.45) | PLD1TRPM8ALDH1A1SMN1; SMN2 | |
| SCHEMBL29591041 | 0.68 | JAK3 (0.45) | PLD1TRPM8ALDH1A1SMN1; SMN2 | |
| SCHEMBL14139451 | 0.67 | LCK (0.58) | TRPM8ALDH1A1SMN1; SMN2LMNAMAPT | |
| SCHEMBL3583332 | 0.67 | HTR1A (0.42) | ALDH1A1SMN1; SMN2HTR7 | |
| Hydrochloric Acid SCHEMBL4133640 | 0.67 | JAK3 (0.44) | PLD1TRPM8ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL27863544 | 0.66 | LCK (0.54) | TRPM8ALDH1A1SMN1; SMN2LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612076-B2 | Piperazinyl-pyridine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090042903-A1 | PIPERAZINYL-PYRIDINE DERIVATIVES | NETTEKOVEN MATTHIAS HEINRICH | 2009-02-12 | — | — | US | disclosed |
| US-7456175-B2 | Piperazinyl-pyridine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20060135528-A1 | Piperazinyl-pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135528-A1 | Piperazinyl-pyridine derivatives | HRH4, HRH3, H1-3 | PLD1 3147/4885TRPM8 810/4885ALDH1A1 814/4885 |
| US-20090042903-A1 | PIPERAZINYL-PYRIDINE DERIVATIVES | HRH4, HRH3, H1-3 | PLD1 3147/4885TRPM8 810/4885ALDH1A1 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.